EIP103 Peptide Degrader Structure for Triple-Negative Breast Cancer

Minxian Li's 2026 study provides Protein Data Bank (PDB) files detailing the structure of the EIP103 peptide degrader targeting the EZH2 protein in triple-negative breast cancer (TNBC). The dataset, approximately 889.4 KB in size, includes molecular dynamics simulation results and biochemical assay data that reveal EIP103's binding mechanism to the EZH2 SET domain. This structural information supports research into novel immunogenic cell death pathways for enhancing immune checkpoint therapy.

Use Cases

• Analyze the binding interface between the EIP103 peptide and the EZH2 SET domain using the provided PDB structure files.
• Validate molecular dynamics simulation trajectories of EIP103-induced conformational destabilization of EZH2.
• Study the structural basis for PJA2-mediated ubiquitination and proteasomal degradation of EZH2 triggered by the peptide degrader.
• Correlate structural features from the PDB files with biochemical assay results on lipid peroxidation and immune cell infiltration.

Strengths

• Data originates from a 2026 study, ensuring recent scientific relevance.
• Includes specific structural data on the first-in-class peptide degrader EIP103, a novel therapeutic candidate.
• Focuses on the high-affinity interaction with the EZH2 SET domain, a key target in TNBC with poor prognoses.

Limitations

• The dataset is small in scale at 889.4 KB, limiting the scope of structural analysis.
• Lacks associated tabular data (e.g., experimental measurements, patient outcomes) for broader statistical modeling.
• Contains only structural biology data (PDB files), requiring specialized bioinformatics tools for analysis.

Provenance

Source

figshare, authored by Minxian Li.

Collection Method

Generated from molecular dynamics simulations and biochemical assays as part of a published study.

Freshness

Last updated March 23, 2026.